Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376691 | 0.82 | CTSS (0.40) | CTSSCTSKNR1D1TRPM8CYP1A2 | |
| SCHEMBL6374144 | 0.78 | ALDH1A1 (0.39) | CTSSCTSKPOLBMEN1KMT2A | |
| SCHEMBL6374135 | 0.78 | ALDH1A1 (0.39) | CTSSCTSKPOLBMEN1KMT2A | |
| SCHEMBL6382464 | 0.78 | ALDH1A1 (0.39) | CTSSCTSKPOLBMEN1KMT2A | |
| SCHEMBL6376502 | 0.78 | CTSS (0.46) | CTSSCTSKPOLBDPP4MAPT | |
| SCHEMBL3116664 | 0.77 | KMT2A (0.35) | NR1D1P2RX7MEN1KMT2ACA2 | |
| SCHEMBL4374409 | 0.77 | KMT2A (0.35) | NR1D1P2RX7MEN1KMT2ACA2 | |
| SCHEMBL3831947 | 0.77 | KMT2A (0.35) | NR1D1P2RX7MEN1KMT2ACA2 | |
| SCHEMBL3119201 | 0.77 | KMT2A (0.35) | NR1D1P2RX7MEN1KMT2ACA2 | |
| SCHEMBL3117255 | 0.75 | CA12 (0.36) | NR1D1MEN1KMT2ACA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185524-B1 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER LAMBERT CO (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | YUEN PO-WAI (US) | 2004-07-01 | — | — | US | claimed |
| JP-2003500486-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1185524-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000073296-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2000-12-07 | — | — | WO | claimed |
| EP-1185524-B1 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER LAMBERT CO (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6833385-B2 | Thiophene derivatives; epilepsy, faintness attacks, depression, anxiety, panic, pain; neurodegenerative, neuropathological and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2004-12-21 | — | — | US | disclosed |
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | YUEN PO-WAI (US) | 2004-07-01 | — | — | US | disclosed |
| US-6710190-B1 | ANTIEPILEPTIC, ANTIDEPRESSANT, ANXIOLYTIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANALGESIC AGENTS; NEURODEGENERATIVE AND GASTROINTESTINAL DISORDERS; IRRITABLE BOWEL SYNDROME | WARNER-LAMBERT COMPANY | 2004-03-23 | — | — | US | disclosed |
| EP-1185524-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000073296-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | GABRB3, GABRB1, GABRB2 | CTSS 423/4885CTSK 923/4885NR1D1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.